Compare Enbridge Inc (ENB) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs McKesson Corporation — how do they compare? Enbridge Inc trades at $46.53 (market cap $103.38B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: Enbridge Inc and McKesson Corporation are close in size by market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and McKesson Corporation for 74 Days on average.
| ENB | MCK | |
|---|---|---|
Market Cap | $103.38B | $108.46B |
Volume | 3,684,305 | 712,607 |
Sector | Energy | Health |
52-Week High | $58.04 | $995.69 |
52-Week Low | $45.23 | $725.17 |
Typical Hold Time | 91 Days | 74 Days |
Enterprise Value | $185.39B | $115.00B |
Dividend Yield | 6.02% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $45.89, down 1.4% on the day, with a bearish technical signal but strong recent earnings beats. The company posted $65.19B in 2025 revenue, with net income of $7.49B and a 7.34% margin. Analysts maintain a consensus buy rating with a $61.63 price target, highlighting a 6% dividend yield and robust cash flow from operations of $12.27B.
Outlook is positive due to consistent EBITDA growth, a $41B project backlog, and defensive midstream assets, though risks include high debt levels and sensitivity to interest rates. The stock offers value with a P/E of 25.54 and P/S of 1.73, supported by institutional interest and dividend stability.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
